Trevi Therapeutics TRVI 深 沪
等待开盘 08-06 09:30:00 美东时间
18.65
-0.100
-0.53%
华盛通- 最 高19.30
- 今 开19.00
- 成交量 150.19万股
- 最 低 18.4639
- 昨 收 18.75
- 总市值 26.48亿
- 52周最高 20.22
- 市盈率 静 --
- 换手率 1.06%
- 52周最低 6.93
- 委 比 -36.84%
- 总股本 1.42亿
- 历史最高 20.22
- 量 比 0.93
- 振 幅 4.46%
- 历史最低 0.46
- 每 手 1
- 风险率 3.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
Trevi Therapeutics, Inc. will host a conference call and webcast on August 6, 2026, at 4:30 p.m. ET, to discuss its financial results and corporate updates for the quarter ended June 30, 2026. The company is developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in IPF, non-IPF ILD, and RCC patients. Haduvio has shown significant reduction in cough frequency and improved patient outcomes. No FDA-approved therapies exist for these co...
07-30 20:05
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
Trevi climbs after late-stage trial setback for GSK cough therapy
After GSK (GSK) announced it would discontinue a chronic cough therapy following a late-stage trial failure, Trevi Therapeutics (TRVI), which is advancing a rival candidate, traded higher to reach an ...
07-18 02:04
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Nasdaq Composite falling around 400 points on Friday. Shares of ManpowerGroup Inc (NYSE:MAN) rose sharply after the company reported upbeat second-quarter results and issued third-quarter earnings guidance above expectations. Adjusted earnings were 99 cents per share...
07-17 22:09
Trevi Therapeutics Announces Upcoming June and July Event Schedule
Trevi Therapeutics, Inc. announced that senior management will attend several key events in June and July 2026, including the BIO International Convention, Leerink Partners Therapeutics Forum, and ERS Cough Conference. The company is developing Haduvio™, an investigational therapy for chronic cough in patients with IPF, non-IPF ILD, and refractory chronic cough (RCC). Haduvio™ has shown statistically significant reductions in cough frequency in c...
06-17 11:30
美股大行评级 | Cava、CrowdStrike、Keysight获多家大行上调目标价；家得宝绩后遭多家大行下调目标价
今日重点评级关注：Oppenheimer：维持Protara Therapeutics"跑赢大市"评级，目标价从25美元升至28美元；Piper Sandler：维持Bright Minds Biosciences"超配"评级，目标价从190美元升至220美元
05-21 12:05
Needham Reiterates Buy on Trevi Therapeutics, Maintains $23 Price Target
Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $23 price target.
05-21 01:15
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
